Breakthrough TB Diagnostic Tech Revolutionizes Healthcare

The Indian Council of Medical Research (ICMR) has successfully transferred an indigenously developed CRISPR-Cas-based diagnostic technology for TB to Meril Diagnostics for commercial production. This innovation, aimed at rapid TB detection, is a pivotal step in India's ambitious TB elimination strategy.

The Indian Council of Medical Research (ICMR) has taken a significant step by transferring a groundbreaking diagnostic technology for tuberculosis (TB) to Meril Diagnostics. This advancement, set for large-scale commercial production, is poised to enhance rapid TB detection across the country.

Developed by the ICMR-Regional Medical Research Centre, North East, this CRISPR-Cas-based technology stands out for its ultra-sensitive and rapid detection capabilities. Entirely conceptualized through the collaboration of experts in molecular biology, engineering, and software development, it marks a stride toward affordable and scalable diagnostics, crucial for underserved regions.

Principal Investigator Dr. Md Atique Ahmed emphasized the innovation's role in bridging high-end molecular biology with practical field utility. The technology aims to bolster India's strategy to identify and treat all TB cases, aligning with the nation's goal of eliminating the disease.

(With inputs from agencies.)